Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jun;5(3):347-9.
doi: 10.21037/tlcr.2016.05.07.

Further results of the FRAGMATIC trial of thromboprophylaxis in lung cancer

Fergus Macbeth  1 , Ben Carter  1 , Simon Noble  1 , Kerenza Hood  1
Affiliations

Further results of the FRAGMATIC trial of thromboprophylaxis in lung cancer

Fergus Macbeth et al. Transl Lung Cancer Res. 2016 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Survival of NSCLC patients [Log Rank P=0.931, unadjusted HR =1.00 (95% CI: 0.90–1.10; P=0.931) adjusted HR =1.01 (95% CI: 0.91–1.12; P=0.856)]. NSCLC, non-small cell lung cancer; HR, hazard ratio.
Figure 2
Figure 2
Survival of SCLC patients [Log Rank P=0.61, unadjusted HR =1.09 (95% CI: 0.88–1.33; P=0.434), adjusted HR =0.93 (95% CI: 0.72–1.20; P=0.769) adjusted for: Site; Sex; ECOG performance status; first treatment; and metastases]. SCLC, small cell lung cancer; HR, hazard ratio.
Figure 3
Figure 3
NSCLC patients VTE-free survival [Log Rank P=0.0097, unadjusted HR =0.65 (95% CI: 0.46–0.90; P=0.010), adjusted HR =0.60 (95% CI: 0.43–0.85; P=0.004)]. NSCLC, non-small cell lung cancer; VTE, venous thromboembolism; HR, hazard ratio.
Figure 4
Figure 4
SCLC patients VTE-free survival [Log rank P=0.0030, unadjusted HR =0.22 (95% CI: 0.08–0.066; P=0.007, adjusted HR =0.25 (95% CI: 0.05–1.29; P=0.097)]. SCLC, small cell lung cancer; VTE, venous thromboembolism; HR, hazard ratio.
See this image and copyright information in PMC

Comment on

  • Transl Lung Cancer Res. 5:280.

References

    1. Macbeth F, Noble S, Evans J, et al. Randomized Phase III Trial of Standard Therapy Plus Low Molecular Weight Heparin in Patients With Lung Cancer: FRAGMATIC Trial. J Clin Oncol 2016;34:488-94. 10.1200/JCO.2015.64.0268 - DOI - PubMed
    1. Altinbas M, Coskun HS, Er O, et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004;2:1266-71. 10.1111/j.1538-7836.2004.00871.x - DOI - PubMed
    1. Lebeau B, Chastang C, Brechot JM, et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. Cancer 1994;74:38-45. 10.1002/1097-0142(19940701)74:1<38::AID-CNCR2820740108>3.0.CO;2-E - DOI - PubMed
    1. Noble S, Robbins A, Alikhan R, et al. Prediction of venous thromboembolism in lung cancer patients receiving chemotherapy. Journal of the International Society of Thrombosis and Haemostasis 2015;13:143.

LinkOut - more resources